{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:21:04Z","timestamp":1791404464105,"version":"4.3.3"},"reference-count":356,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006518","name":"University of Nebraska Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006518","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016302","name":"Coalition for Epidemic Preparedness Innovations","doi-asserted-by":"publisher","award":["mRNA-1273"],"award-info":[{"award-number":["mRNA-1273"]}],"id":[{"id":"10.13039\/100016302","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.addr.2021.01.002","type":"journal-article","created":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T07:48:07Z","timestamp":1610351287000},"page":"215-239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":95,"special_numbering":"C","title":["Nanocarrier vaccines for SARS-CoV-2"],"prefix":"10.1016","volume":"171","author":[{"given":"Jatin","family":"Machhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Shahjin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srijanee","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milankumar","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai Mohamed","family":"Abdelmoaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preet Amol","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Baldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Bajwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalit K.","family":"Vora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapan A.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxim D.","family":"Oleynikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhruvkumar","family":"Soni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pravin","family":"Yeapuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Insiya","family":"Mukadam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajashree","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline G.","family":"Saksena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Herskovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmudul","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Oupicky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suvarthi","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan F.","family":"Donnelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth S.","family":"Hettie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard E.","family":"Gendelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavesh D.","family":"Kevadiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2021.01.002_bb0005","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","article-title":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia","volume":"382","author":"Li","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2021.01.002_bb0010","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/s41564-020-0695-z","volume":"5","year":"2020","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.addr.2021.01.002_bb0015","author":"World Health Organization"},{"key":"10.1016\/j.addr.2021.01.002_bb0020","doi-asserted-by":"crossref","first-page":"795","DOI":"10.15585\/mmwr.mm6925e2","article-title":"Potential indirect effects of the COVID-19 pandemic on use of emergency departments for acute life-threatening conditions \u2014 United States","volume":"69","author":"Lange","year":"2020","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"10.1016\/j.addr.2021.01.002_bb0025","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11481-020-09944-5","article-title":"The natural history, pathobiology, and clinical manifestations of SARS-CoV-2 infections","volume":"15","author":"Machhi","year":"2020","journal-title":"J. NeuroImmune Pharmacol."},{"key":"10.1016\/j.addr.2021.01.002_bb0030","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cytogfr.2020.04.002","article-title":"Cytokine storm intervention in the early stages of COVID-19 pneumonia","volume":"53","author":"Sun","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.addr.2021.01.002_bb0035","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1152\/physiolgenomics.00033.2020","article-title":"Harnessing innate immunity to eliminate SARS-CoV-2 and ameliorate COVID-19 disease","volume":"52","author":"Golonka","year":"2020","journal-title":"Physiol. Genomics"},{"key":"10.1016\/j.addr.2021.01.002_bb0040","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.cell.2020.04.026","article-title":"Imbalanced host response to SARS-CoV-2 drives development of COVID-19","volume":"181","author":"Blanco-Melo","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.addr.2021.01.002_bb0045","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41392-020-00243-2","article-title":"COVID-19: immunopathogenesis and immunotherapeutics","volume":"5","author":"Yang","year":"2020","journal-title":"Signal. Transduct. Target Ther."},{"key":"10.1016\/j.addr.2021.01.002_bb0050","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.immuni.2020.03.007","article-title":"SARS-CoV-2 vaccines: status report","volume":"52","author":"Amanat","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.addr.2021.01.002_bb0060","author":"World Health Organization"},{"key":"10.1016\/j.addr.2021.01.002_bb0065","author":"McKinsey & Company"},{"key":"10.1016\/j.addr.2021.01.002_bb0070","author":"U.S. Food and Drug Administration"},{"key":"10.1016\/j.addr.2021.01.002_bb0075","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1126\/science.abc5312","article-title":"A strategic approach to COVID-19 vaccine R&D","volume":"368","author":"Corey","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.addr.2021.01.002_bb0080","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1056\/NEJMp2005630","article-title":"Developing Covid-19 vaccines at pandemic speed","volume":"382","author":"Lurie","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2021.01.002_bb0085","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/s41565-020-0737-y","article-title":"COVID-19 vaccine development and a potential nanomaterial path forward","volume":"15","author":"Shin","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.addr.2021.01.002_bb0090","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomized controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2021.01.002_bb0095","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/d41573-020-00016-0","article-title":"Therapeutic options for the 2019 novel coronavirus (2019-nCoV), Nat","volume":"19","author":"Li","year":"2020","journal-title":"Rev. Drug Discov"},{"key":"10.1016\/j.addr.2021.01.002_bb0100","first-page":"1824","article-title":"Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review","volume":"323","author":"Sanders","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2021.01.002_bb0105","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1021\/acscentsci.0c00272","article-title":"Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases","volume":"6","author":"Liu","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.addr.2021.01.002_bb0110","doi-asserted-by":"crossref","first-page":"106924","DOI":"10.1016\/j.intimp.2020.106924","article-title":"Immunotherapeutic approaches to curtail COVID-19","volume":"88","author":"Owji","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.addr.2021.01.002_bb0115","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.mayocp.2020.05.024","article-title":"Innovation lessons from the COVID-19 pandemic","volume":"95","author":"Farrugia","year":"2020","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.addr.2021.01.002_bb0120","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1126\/science.1116480","article-title":"Structure of SARS coronavirus spike receptor-binding domain complexed with receptor","volume":"309","author":"Li","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.addr.2021.01.002_bb0125","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.addr.2021.01.002_bb0130","doi-asserted-by":"crossref","first-page":"104697","DOI":"10.1016\/j.antiviral.2019.104697","article-title":"In silico and in vitro analysis of small molecules and natural compounds targeting the 3CL protease of feline infectious peritonitis virus","volume":"174","author":"Theerawatanasirikul","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.addr.2021.01.002_bb0135","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMe2020388","article-title":"Hydroxychloroquine for the prevention of Covid-19 - searching for evidence","volume":"383","author":"Cohen","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2021.01.002_bb0140","doi-asserted-by":"crossref","first-page":"106101","DOI":"10.1016\/j.ijantimicag.2020.106101","article-title":"Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal","volume":"56","author":"Khuroo","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.addr.2021.01.002_bb0145","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","volume":"6","author":"Liu","year":"2020","journal-title":"Cell Discov."},{"key":"10.1016\/j.addr.2021.01.002_bb0150","doi-asserted-by":"crossref","first-page":"754","DOI":"10.7326\/M20-1334","article-title":"Use of hydroxychloroquine and chloroquine during the COVID-19 pandemic: what every clinician should know","volume":"172","author":"Yazdany","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.addr.2021.01.002_bb0155","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/348600a0","article-title":"Intracellular transport of class II MHC molecules directed by invariant chain","volume":"348","author":"Lotteau","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.addr.2021.01.002_bb0160","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13075-017-1393-y","article-title":"Hydroxychloroquine inhibits CD154 expression in CD4(+) T lymphocytes of systemic lupus erythematosus through NFAT, but not STAT5, signalling","volume":"19","author":"Wu","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.addr.2021.01.002_bb0165","first-page":"55","article-title":"Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells","volume":"24","author":"van den Borne","year":"1997","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.addr.2021.01.002_bb0170","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.4049\/jimmunol.1000702","article-title":"Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines","volume":"186","author":"Kuznik","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2021.01.002_bb0175","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nature07405","article-title":"The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor","volume":"456","author":"Ewald","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.addr.2021.01.002_bb0180","doi-asserted-by":"crossref","first-page":"6230","DOI":"10.1093\/emboj\/17.21.6230","article-title":"CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation","volume":"17","author":"Hacker","year":"1998","journal-title":"EMBO J."},{"key":"10.1016\/j.addr.2021.01.002_bb0185","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1084\/jem.20051696","article-title":"Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8","volume":"202","author":"Vollmer","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.addr.2021.01.002_bb0190","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.4049\/jimmunol.1402793","article-title":"Cutting edge: antimalarial drugs inhibit IFN-beta production through blockade of cyclic GMP-AMP synthase-DNA interaction","volume":"194","author":"An","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2021.01.002_bb0195","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1158\/1078-0432.CCR-13-3227","article-title":"Hydroxychloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer","volume":"20","author":"Cook","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2021.01.002_bb0200","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.celrep.2018.06.065","article-title":"Autophagy is a tolerance-avoidance mechanism that modulates TCR-mediated signalling and cell metabolism to prevent induction of T cell anergy","volume":"24","author":"Mocholi","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.addr.2021.01.002_bb0205","author":"U.S. Food and Drug Administration"},{"key":"10.1016\/j.addr.2021.01.002_bb0210","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJMoa2016638","article-title":"A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19","volume":"383","author":"Boulware","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2021.01.002_bb0215","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A Trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2021.01.002_bb0220","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/jmv.25729","article-title":"A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option","volume":"92","author":"Yao","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.addr.2021.01.002_bb0225","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ijid.2020.05.085","article-title":"Lack of antiviral activity of darunavir against SARS-CoV-2","volume":"97","author":"De Meyer","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.addr.2021.01.002_bb0230","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1021\/acs.jmedchem.6b01594","article-title":"Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of ebola and emerging viruses","volume":"60","author":"Siegel","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2021.01.002_bb0235","doi-asserted-by":"crossref","first-page":"101615","DOI":"10.1016\/j.tmaid.2020.101615","article-title":"Remdesivir as a possible therapeutic option for the COVID-19","volume":"34","author":"Al-Tawfiq","year":"2020","journal-title":"Travel Med. Infect. Dis."},{"key":"10.1016\/j.addr.2021.01.002_bb0240","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19 - preliminary report","volume":"383","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2021.01.002_bb0245","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomized, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2021.01.002_bb0250","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe Covid-19","volume":"382","author":"Grein","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2021.01.002_bb0255","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1001\/jama.2020.22240","article-title":"Effect of hydroxychloroquine on clinical status at 14\u00a0days in hospitalized patients with COVID-19: a randomized clinical trial","volume":"324","author":"Self","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2021.01.002_bb0260","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030343","article-title":"SARS: systematic review of treatment effects","volume":"3","author":"Stockman","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.addr.2021.01.002_bb0265","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"10.1016\/j.addr.2021.01.002_bb0270","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.addr.2021.01.002_bb0275","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1038\/s41467-020-18463-z","article-title":"Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis","volume":"11","author":"Shannon","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2021.01.002_bb0280","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.mjafi.2020.08.004","article-title":"Favipiravir: A new and emerging antiviral option in COVID-19","volume":"76","author":"Agrawal","year":"2020","journal-title":"Med. J. Armed Forces India"},{"key":"10.1016\/j.addr.2021.01.002_bb0285","article-title":"Favipiravir versus arbidol for COVID-19: a randomized clinical trial","author":"Chen","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.addr.2021.01.002_bb0290","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/s41418-020-0530-3","article-title":"COVID-19 infection: the perspectives on immune responses","volume":"27","author":"Shi","year":"2020","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.addr.2021.01.002_bb0295","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2107","article-title":"Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS","volume":"30","author":"Rokni","year":"2020","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.addr.2021.01.002_bb0300","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.3389\/fimmu.2020.01512","article-title":"Flattening the COVID-19 curve with natural killer cell based immunotherapies","volume":"11","author":"Market","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2021.01.002_bb0305","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S1473-3099(20)30141-9","article-title":"Convalescent plasma as a potential therapy for COVID-19","volume":"20","author":"Chen","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.addr.2021.01.002_bb0310","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11906-020-1034-8","article-title":"Emerging therapeutic potential of mesenchymal stem\/stromal cells in preeclampsia","volume":"22","author":"Suvakov","year":"2020","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.addr.2021.01.002_bb0315","doi-asserted-by":"crossref","DOI":"10.3390\/cells9040924","article-title":"Mesenchymal stromal cell secretome for severe COVID-19 infections: premises for the therapeutic use","volume":"9","author":"Bari","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.addr.2021.01.002_bb0320","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/s41591-020-1088-9","article-title":"Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study","volume":"26","author":"Liu","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2021.01.002_bb0325","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/jama.2020.4940","article-title":"Convalescent plasma to treat COVID-19: possibilities and challenges","volume":"323","author":"Roback","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2021.01.002_bb0330","author":"BioPharma-Reporter"},{"key":"10.1016\/j.addr.2021.01.002_bb0335","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1469-0691.2004.00956.x","article-title":"Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients","volume":"10","author":"Soo","year":"2004","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.addr.2021.01.002_bb0340","first-page":"1153","article-title":"Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic Influenza A (H7N9) infection, a hint for COVID-19 treatment","volume":"6","author":"Chen","year":"2020","journal-title":"Engineering (Beijing)"},{"key":"10.1016\/j.addr.2021.01.002_bb0345","doi-asserted-by":"crossref","first-page":"852","DOI":"10.7326\/L20-0681","article-title":"Regulatory T cells for treating patients with COVID-19 and acute respiratory distress syndrome: two case reports","volume":"173","author":"Gladstone","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.addr.2021.01.002_bb0350","first-page":"539","article-title":"Regulatory T cells tested in patients with COVID-19 ARDS","volume":"324","author":"Abbasi","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2021.01.002_bb0355","author":"PR Newswire, Cellenkos Inc"},{"key":"10.1016\/j.addr.2021.01.002_bb0360","first-page":"25","article-title":"Antibody-dependent enhancement of SARS coronavirus infection and its role in the pathogenesis of SARS","volume":"22","author":"Yip","year":"2016","journal-title":"Hong Kong Med. J."},{"key":"10.1016\/j.addr.2021.01.002_bb0365","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41577-020-0303-8","article-title":"Dysregulation of lung myeloid cells in COVID-19","volume":"20","author":"Salome","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2021.01.002_bb0370","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/annrheumdis-2015-207628","article-title":"Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomized controlled trial","volume":"75","author":"Burmester","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.addr.2021.01.002_bb0375","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1136\/annrheumdis-2015-207818","article-title":"Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1\u00a0year of postmarketing surveillance follow-up of 417 patients in Japan","volume":"75","author":"Yokota","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.addr.2021.01.002_bb0380","article-title":"A systematic review of Anakinra, Tocilizumab, Sarilumab and Siltuximab for coronavirus-related infections","author":"Khan","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.addr.2021.01.002_bb0385","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.tips.2020.06.007","article-title":"Targeting JAK-STAT signalling to control cytokine release syndrome in COVID-19","volume":"41","author":"Luo","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.addr.2021.01.002_bb0390","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jmii.2020.03.005","article-title":"TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib","volume":"53","author":"Wu","year":"2020","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"10.1016\/j.addr.2021.01.002_bb0395","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1473-3099(20)30132-8","article-title":"COVID-19: combining antiviral and anti-inflammatory treatments","volume":"20","author":"Stebbing","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.addr.2021.01.002_bb0400","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41577-020-0312-7","article-title":"COVID-19: risk for cytokine targeting in chronic inflammatory diseases?","volume":"20","author":"Schett","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2021.01.002_bb0405","author":"Kleo Pharmaceuticals"},{"key":"10.1016\/j.addr.2021.01.002_bb0410","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41582-020-0385-8","article-title":"Neurological immunotherapy in the era of COVID-19 - looking for consensus in the literature","volume":"16","author":"Korsukewitz","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.addr.2021.01.002_bb0415","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.immuni.2020.04.012","article-title":"Herd immunity: understanding COVID-19","volume":"52","author":"Randolph","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.addr.2021.01.002_bb0420","first-page":"e32","article-title":"Herd immunity - estimating the level required to halt the COVID-19 epidemics in affected countries","volume":"80","author":"Kwok","year":"2020","journal-title":"J. Inf. Secur."},{"key":"10.1016\/j.addr.2021.01.002_bb0425","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00150-11","article-title":"Why do influenza virus subtypes die out? A hypothesis","volume":"2","author":"Palese","year":"2011","journal-title":"mBio"},{"key":"10.1016\/j.addr.2021.01.002_bb0430","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1111\/tbed.13515","article-title":"Control of avian influenza in China: Strategies and lessons","volume":"67","author":"Liu","year":"2020","journal-title":"Transbound. Emerg. Dis."},{"key":"10.1016\/j.addr.2021.01.002_bb0435","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1007\/s11427-018-9420-1","article-title":"Vaccination of poultry successfully eliminated human infection with H7N9 virus in China","volume":"61","author":"Zeng","year":"2018","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.addr.2021.01.002_bb0440","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/d41586-020-02948-4","article-title":"The false promise of herd immunity for COVID-19","volume":"587","author":"Aschwanden","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.addr.2021.01.002_bb0445","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/318323a0","article-title":"Vaccination and herd immunity to infectious diseases","volume":"318","author":"Anderson","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.addr.2021.01.002_bb0450","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jaci.2018.05.007","article-title":"Vaccination-induced herd immunity: Successes and challenges","volume":"142","author":"Mallory","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.addr.2021.01.002_bb0455","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1002\/jmv.25870","article-title":"COVID-19: Herd immunity and convalescent plasma transfer therapy","volume":"92","author":"Syal","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.addr.2021.01.002_bb0460","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1473-3099(20)30120-1","article-title":"An interactive web-based dashboard to track COVID-19 in real time","volume":"20","author":"Dong","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.addr.2021.01.002_bb0465","first-page":"1","article-title":"Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare demand","author":"Ferguson","year":"2020","journal-title":"Imperical College London"},{"key":"10.1016\/j.addr.2021.01.002_bb0470","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.hlpt.2020.08.009","article-title":"Swedish policy analysis for Covid-19","volume":"9","author":"Kavaliunas","year":"2020","journal-title":"Health Policy Technol."},{"key":"10.1016\/j.addr.2021.01.002_bb0475","first-page":"732","article-title":"Difficult to determine herd immunity threshold for COVID-19","volume":"324","author":"Rubin","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2021.01.002_bb0480","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1440-1843.2006.00783.x","article-title":"Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance","volume":"11","author":"Mo","year":"2006","journal-title":"Respirology"},{"key":"10.1016\/j.addr.2021.01.002_bb0485","doi-asserted-by":"crossref","first-page":"7264","DOI":"10.4049\/jimmunol.0903490","article-title":"Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study","volume":"186","author":"Tang","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2021.01.002_bb0490","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1126\/science.abb5793","article-title":"Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period","volume":"368","author":"Kissler","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.addr.2021.01.002_bb0495","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1093\/cid\/ciaa344","article-title":"Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019","volume":"71","author":"Zhao","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.addr.2021.01.002_bb0500","article-title":"Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications","author":"Wu","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.addr.2021.01.002_bb0505","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1001\/jama.2020.2783","article-title":"Positive RT-PCR test results in patients recovered from COVID-19","volume":"323","author":"Lan","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2021.01.002_bb0510","doi-asserted-by":"crossref","DOI":"10.12659\/AJCR.927812","article-title":"A 63-year-old woman with a history of non-hodgkin lymphoma with persistent SARS-CoV-2 infection who was seronegative and treated with convalescent plasma","volume":"21","author":"Moore","year":"2020","journal-title":"Am. J. Case Rep."},{"key":"10.1016\/j.addr.2021.01.002_bb0515","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1007\/s10067-020-05427-3","article-title":"COVID-19 reinfection or relapse: an intriguing dilemma","volume":"39","author":"Madan","year":"2020","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.addr.2021.01.002_bb0520","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1038\/s41564-020-00813-8","article-title":"Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans","volume":"5","author":"Seow","year":"2020","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.addr.2021.01.002_bb0525","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00567-20","article-title":"International expansion of a novel SARS-CoV-2 mutant","volume":"94","author":"Wang","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2021.01.002_bb0530","author":"World Health Organization"},{"key":"10.1016\/j.addr.2021.01.002_bb0535","author":"Centers for Disease Control & Prevention"},{"key":"10.1016\/j.addr.2021.01.002_bb0540","author":"CNN"},{"key":"10.1016\/j.addr.2021.01.002_bb0545","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/1040841X.2020.1739001","article-title":"Emergence of novel coronavirus and COVID-19: whether to stay or die out?","volume":"46","author":"Biswas","year":"2020","journal-title":"Crit. Rev. Microbiol."},{"key":"10.1016\/j.addr.2021.01.002_bb0550","series-title":"Infectious Agents and How They Cause Disease","first-page":"455","article-title":"Immunobiology: the immune system in health and disease","author":"Janeway","year":"2001"},{"key":"10.1016\/j.addr.2021.01.002_bb0555","series-title":"Molecular Biology of the Cell. Pathogens and Infection","first-page":"1263","author":"Alberts","year":"2002"},{"key":"10.1016\/j.addr.2021.01.002_bb0560","series-title":"Essential Human Virology","first-page":"19","article-title":"Chapter 2 - virus structure and classification","author":"Louten","year":"2016"},{"key":"10.1016\/j.addr.2021.01.002_bb0565","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/cei.13295","article-title":"Emerging viruses and current strategies for vaccine intervention","volume":"196","author":"Afrough","year":"2019","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.addr.2021.01.002_bb0570","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1126\/science.aac6300","article-title":"PUBLIC HEALTH. Toward an HIV vaccine: a scientific journey","volume":"349","author":"Fauci","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.addr.2021.01.002_bb0575","doi-asserted-by":"crossref","first-page":"8218","DOI":"10.1073\/pnas.2005456117","article-title":"Avoiding pitfalls in the pursuit of a COVID-19 vaccine","volume":"117","author":"Peeples","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2021.01.002_bb0580","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/d41573-020-00073-5","article-title":"The COVID-19 vaccine development landscape","volume":"19","author":"Thanh Le","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2021.01.002_bb0585","doi-asserted-by":"crossref","first-page":"117956","DOI":"10.1016\/j.lfs.2020.117956","article-title":"Vaccination strategies to combat novel corona virus SARS-CoV-2","volume":"256","author":"Pandey","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.addr.2021.01.002_bb0590","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1038\/nm1218","article-title":"The process development challenge for a new vaccine","volume":"11","author":"Buckland","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2021.01.002_bb0595","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3389\/fpubh.2015.00269","article-title":"Vaccines through centuries: major cornerstones of global health","volume":"3","author":"Hajj Hussein","year":"2015","journal-title":"Front. Public Health"},{"key":"10.1016\/j.addr.2021.01.002_bb0600","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/emmm.201403876","article-title":"Vaccines for the 21st century","volume":"6","author":"Delany","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.addr.2021.01.002_bb0605","series-title":"New Generation Vaccines","year":"1997"},{"key":"10.1016\/j.addr.2021.01.002_bb0610","series-title":"Immunization Against Infectious Disease","year":"2006"},{"key":"10.1016\/j.addr.2021.01.002_bb0615","doi-asserted-by":"crossref","first-page":"35","DOI":"10.7774\/cevr.2012.1.1.35","article-title":"Principles underlying rational design of live attenuated influenza vaccines","volume":"1","author":"Jang","year":"2012","journal-title":"Clin. Exp. Vaccine Res."},{"key":"10.1016\/j.addr.2021.01.002_bb0620","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7774\/cevr.2012.1.1.18","article-title":"A review of vaccine development and research for industry animals in Korea","volume":"1","author":"Lee","year":"2012","journal-title":"Clin. Exp. Vaccine Res."},{"key":"10.1016\/j.addr.2021.01.002_bb0625","first-page":"635","article-title":"The double-edged sword: How evolution can make or break a live-attenuated virus vaccine","volume":"4","author":"Hanley","year":"2011","journal-title":"Evolution"},{"key":"10.1016\/j.addr.2021.01.002_bb0630","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.virol.2015.03.032","article-title":"Historical successes and current challenges","volume":"479\u2013480","author":"Minor","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.addr.2021.01.002_bb0635","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4103\/0974-777X.77299","article-title":"Fundamentals of vaccine immunology","volume":"3","author":"Clem","year":"2011","journal-title":"J. Global Infect. Dis."},{"key":"10.1016\/j.addr.2021.01.002_bb0640","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.virol.2005.09.020","article-title":"Replication-defective viruses as vaccines and vaccine vectors","volume":"344","author":"Dudek","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.addr.2021.01.002_bb0645","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/jgm.206","article-title":"Preclinical safety testing of DISC-hGMCSF to support phase I clinical trials in cancer patients","volume":"3","author":"Loudon","year":"2001","journal-title":"J. Gene Med."},{"key":"10.1016\/j.addr.2021.01.002_bb0650","doi-asserted-by":"crossref","first-page":"7067","DOI":"10.1128\/jvi.66.12.7067-7072.1992","article-title":"Replication-defective mutants of herpes simplex virus (HSV) induce cellular immunity and protect against lethal HSV infection","volume":"66","author":"Nguyen","year":"1992","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2021.01.002_bb0655","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/viro.1996.0328","article-title":"Mechanisms of immunization with a replication-defective mutant of herpes simplex virus 1","volume":"220","author":"Morrison","year":"1996","journal-title":"Virology"},{"key":"10.1016\/j.addr.2021.01.002_bb0660","doi-asserted-by":"crossref","first-page":"7963","DOI":"10.1128\/JVI.74.17.7963-7971.2000","article-title":"Construction, phenotypic analysis, and immunogenicity of a UL5\/UL29 double deletion mutant of herpes simplex virus 2","volume":"74","author":"Da Costa","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2021.01.002_bb0665","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1378\/chest.12-1711","article-title":"Immunobiology of influenza vaccines","volume":"143","author":"Gomez Lorenzo","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.addr.2021.01.002_bb0670","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/ni.2039","article-title":"Immunological mechanisms of vaccination","volume":"12","author":"Pulendran","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.addr.2021.01.002_bb0675","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.3389\/fimmu.2019.01250","article-title":"Attenuation of human respiratory viruses by synonymous genome recoding","volume":"10","author":"Le Nouen","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2021.01.002_bb0680","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01704-14","article-title":"Refining the balance of attenuation and immunogenicity of respiratory syncytial virus by targeted codon deoptimization of virulence genes","volume":"5","author":"Meng","year":"2014","journal-title":"mBio"},{"key":"10.1016\/j.addr.2021.01.002_bb0685","first-page":"6","volume":"38","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2021.01.002_bb0690","author":"Pharmaceutical Technology"},{"key":"10.1016\/j.addr.2021.01.002_bb0695","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/nbt1261","article-title":"Vaccine manufacturing: challenges and solutions","volume":"24","author":"Ulmer","year":"2006","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2021.01.002_bb0700","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/jama.2020.15543","article-title":"Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials","volume":"324","author":"Xia","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2021.01.002_bb0705","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2105\/AJPH.44.5.563","article-title":"Formaldehyde treatment and safety testing of experimental poliomyelitis vaccines","volume":"44","author":"Salk","year":"1954","journal-title":"Am. J. Public Health Nations Health"},{"key":"10.1016\/j.addr.2021.01.002_bb0710","doi-asserted-by":"crossref","first-page":"470","DOI":"10.15585\/mmwr.mm6518a4","article-title":"Progress toward polio eradication - worldwide, 2015\u20132016","volume":"65","author":"Morales","year":"2016","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"10.1016\/j.addr.2021.01.002_bb0715","doi-asserted-by":"crossref","first-page":"6655","DOI":"10.1016\/j.vaccine.2016.10.016","article-title":"Vaccine development: from concept to early clinical testing","volume":"34","author":"Cunningham","year":"2016","journal-title":"Vaccine"},{"issue":"Suppl. 3","key":"10.1016\/j.addr.2021.01.002_bb0720","doi-asserted-by":"crossref","first-page":"S266","DOI":"10.1086\/313883","article-title":"Improving vaccine performance with adjuvants","volume":"30","author":"Vogel","year":"2000","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.addr.2021.01.002_bb0725","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.abc1932","article-title":"Development of an inactivated vaccine candidate for SARS-CoV-2","volume":"369","author":"Gao","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.addr.2021.01.002_bb0730","author":"SINOVAC"},{"key":"10.1016\/j.addr.2021.01.002_bb0735","author":"ContagionLive"},{"key":"10.1016\/j.addr.2021.01.002_bb0740","author":"Wire"},{"key":"10.1016\/j.addr.2021.01.002_bb0745","series-title":"Lancet Infect Dis","article-title":"A promising inactivated whole-virion SARS-CoV-2 vaccine","author":"Isakova-Sivak","year":"2020"},{"key":"10.1016\/j.addr.2021.01.002_bb0750","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1089\/hum.2006.17.1051","article-title":"DNA vaccines: recent developments and future possibilities","volume":"17","author":"Liu","year":"2006","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.addr.2021.01.002_bb0755","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/sj.gt.3301117","article-title":"The promise of nucleic acid vaccines","volume":"7","author":"Restifo","year":"2000","journal-title":"Gene Ther."},{"key":"10.1016\/j.addr.2021.01.002_bb0760","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1093\/infdis\/jir054","article-title":"A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial","volume":"203","author":"Ledgerwood","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.addr.2021.01.002_bb0765","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.1016\/j.vaccine.2011.04.043","article-title":"A DNA vaccine encoding ubiquitinated Rift Valley fever virus nucleoprotein provides consistent immunity and protects IFNAR(\u2212\/\u2212) mice upon lethal virus challenge","volume":"29","author":"Boshra","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.002_bb0770","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000928","article-title":"A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates","volume":"5","author":"Mallilankaraman","year":"2011","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.addr.2021.01.002_bb0775","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/infdis\/jiy537","article-title":"Protective efficacy and long-term immunogenicity in cynomolgus macaques by Ebola virus glycoprotein synthetic DNA vaccines","volume":"219","author":"Patel","year":"2019","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.addr.2021.01.002_bb0780","article-title":"The increase of the magnitude of spontaneous viral blips in some participants of phase II clinical trial of therapeutic optimized HIV DNA vaccine candidate","volume":"7","author":"Akulova","year":"2019","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.addr.2021.01.002_bb0785","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.3389\/fimmu.2019.01522","article-title":"T cell responses induced by DNA vaccines based on the DENV2 E and NS1 proteins in mice: importance in protection and immunodominant epitope identification","volume":"10","author":"Pinto","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2021.01.002_bb0790","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature02463","article-title":"A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice","volume":"428","author":"Yang","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.addr.2021.01.002_bb0795","author":"PipelineReview"},{"key":"10.1016\/j.addr.2021.01.002_bb0800","author":"BusinessLine"},{"key":"10.1016\/j.addr.2021.01.002_bb0805","author":"BioWorld"},{"key":"10.1016\/j.addr.2021.01.002_bb0810","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3390\/vaccines2030624","article-title":"Developments in viral vector-based vaccines","volume":"2","author":"Ura","year":"2014","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.addr.2021.01.002_bb0815","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.coviro.2011.07.009","article-title":"Viruses - from pathogens to vaccine carriers","volume":"1","author":"Small","year":"2011","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.addr.2021.01.002_bb0820","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.coi.2011.03.006","article-title":"Viral vectors as vaccine platforms: deployment in sight","volume":"23","author":"Rollier","year":"2011","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.addr.2021.01.002_bb0825","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23123310","article-title":"Self-replicating RNA viruses for RNA therapeutics","volume":"23","author":"Lundstrom","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.addr.2021.01.002_bb0830","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1016\/j.vaccine.2007.01.064","article-title":"Attenuated measles virus as a vaccine vector","volume":"25","author":"Zuniga","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.002_bb0835","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1016\/j.vaccine.2005.04.024","article-title":"A recombinant live attenuated measles vaccine vector primes effective HLA-A0201-restricted cytotoxic T lymphocytes and broadly neutralizing antibodies against HIV-1 conserved epitopes","volume":"23","author":"Lorin","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.002_bb0840","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1128\/JVI.78.1.146-157.2004","article-title":"A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV","volume":"78","author":"Lorin","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2021.01.002_bb0845","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1080\/21645515.2015.1122146","article-title":"Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination","volume":"12","author":"Baldo","year":"2016","journal-title":"Hum. Vaccin Immunother."},{"key":"10.1016\/j.addr.2021.01.002_bb0850","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cimid.2007.07.012","article-title":"Recombinant vector derived from live attenuated measles virus: potential for flavivirus vaccines","volume":"31","author":"Brandler","year":"2008","journal-title":"Comp. Immunol. Microbiol. Infect. Dis."},{"key":"10.1016\/j.addr.2021.01.002_bb0855","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040385","article-title":"A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity","volume":"7","author":"Dicks","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2021.01.002_bb0860","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2174\/1566523213666131125095046","article-title":"Adenovirus vectors for gene therapy, vaccination and cancer gene therapy","volume":"13","author":"Wold","year":"2013","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.addr.2021.01.002_bb0865","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00298-16","article-title":"Multivalent and multipathogen viral vector vaccines","volume":"24","author":"Lauer","year":"2017","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.addr.2021.01.002_bb0870","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/imm.12829","article-title":"Novel viral vectors in infectious diseases","volume":"153","author":"Humphreys","year":"2018","journal-title":"Immunology"},{"key":"10.1016\/j.addr.2021.01.002_bb0875","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ymthe.2004.07.013","article-title":"Adenoviruses as vaccine vectors","volume":"10","author":"Tatsis","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2021.01.002_bb0880","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1128\/JVI.02055-12","article-title":"Comparative analysis of simian immunodeficiency virus gag-specific effector and memory CD8+ T cells induced by different adenovirus vectors","volume":"87","author":"Tan","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2021.01.002_bb0885","doi-asserted-by":"crossref","first-page":"313","DOI":"10.7326\/M15-0880","article-title":"Assessment of the safety and immunogenicity of 2 novel vaccine platforms for HIV-1 prevention: a randomized trial","volume":"164","author":"Baden","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.addr.2021.01.002_bb0890","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3389\/fimmu.2020.00909","article-title":"Factors which contribute to the immunogenicity of non-replicating adenoviral vectored vaccines","volume":"11","author":"Coughlan","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2021.01.002_bb0895","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2174\/1566523214666140302193709","article-title":"Basic biology of adeno-associated virus (AAV) vectors used in gene therapy","volume":"14","author":"Balakrishnan","year":"2014","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.addr.2021.01.002_bb0900","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1126\/science.aaw2900","article-title":"Comprehensive AAV capsid fitness landscape reveals a viral gene and enables machine-guided design","volume":"366","author":"Ogden","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.addr.2021.01.002_bb0905","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1128\/JVI.79.2.955-965.2005","article-title":"Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques","volume":"79","author":"Johnson","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2021.01.002_bb0910","first-page":"255","article-title":"Engineering adeno-associated virus vectors for gene therapy, Nat","volume":"21","author":"Li","year":"2020","journal-title":"Rev. Gen. Therm."},{"key":"10.1016\/j.addr.2021.01.002_bb0915","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-020-2607-z","article-title":"Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques","volume":"586","author":"Mercado","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.addr.2021.01.002_bb0920","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1126\/science.abc6284","article-title":"DNA vaccine protection against SARS-CoV-2 in rhesus macaques","volume":"369","author":"Yu","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.addr.2021.01.002_bb0925","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1126\/science.abc4776","article-title":"SARS-CoV-2 infection protects against rechallenge in rhesus macaques","volume":"369","author":"Chandrashekar","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.addr.2021.01.002_bb0930","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomized phase 1\/2 studies from Russia","volume":"396","author":"Logunov","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2021.01.002_bb0935","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1016\/S2213-2600(20)30402-1","article-title":"The Russian vaccine for COVID-19","volume":"8","author":"Burki","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.addr.2021.01.002_bb0940","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomized, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2021.01.002_bb0945","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18\u00a0years or older: a randomized, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2021.01.002_bb0950","author":"News18"},{"key":"10.1016\/j.addr.2021.01.002_bb0955","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41586-020-2608-y","article-title":"ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques","volume":"586","author":"van Doremalen","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.addr.2021.01.002_bb0960","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomized, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2021.01.002_bb0965","author":"AstraZeneca"},{"key":"10.1016\/j.addr.2021.01.002_bb0970","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0168-1656(99)00107-8","article-title":"Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines","volume":"73","author":"Liljeqvist","year":"1999","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.addr.2021.01.002_bb0975","article-title":"Recent advances in subunit vaccine carriers","volume":"4","author":"Vartak","year":"2016","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.addr.2021.01.002_bb0980","first-page":"1488","article-title":"Protein subunit vaccines: example of vaccination against hepatitis B virus","volume":"45","author":"Degos","year":"1995","journal-title":"Rev. Prat."},{"key":"10.1016\/j.addr.2021.01.002_bb0985","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.shpsc.2017.05.004","article-title":"Biotechnology and the transformation of vaccine innovation: the case of the hepatitis B vaccines 1968\u20132000","volume":"64","author":"Huzair","year":"2017","journal-title":"Stud. Hist. Phil. Biol. Biomed. Sci."},{"key":"10.1016\/j.addr.2021.01.002_bb0990","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/cben.201600002","article-title":"Production and purification of recombinant proteins from Escherichia coli","volume":"3","author":"Tripathi","year":"2016","journal-title":"ChemBioEng Rev."},{"key":"10.1016\/j.addr.2021.01.002_bb0995","doi-asserted-by":"crossref","first-page":"953","DOI":"10.4014\/jmb.1412.12079","article-title":"Production of biopharmaceuticals in E. coli: current scenario and future perspectives","volume":"25","author":"Baeshen","year":"2015","journal-title":"J. Microbiol. Biotechnol."},{"key":"10.1016\/j.addr.2021.01.002_bb1000","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s10295-013-1235-0","article-title":"Current state and recent advances in biopharmaceutical production in Escherichia coli, yeasts and mammalian cells","volume":"40","author":"Berlec","year":"2013","journal-title":"J. Ind. Microbiol. Biotechnol."},{"key":"10.1016\/j.addr.2021.01.002_bb1005","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s00253-010-3019-z","article-title":"Production of recombinant proteins and metabolites in yeasts: when are these systems better than bacterial production systems?","volume":"89","author":"Porro","year":"2011","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.addr.2021.01.002_bb1010","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.virol.2005.09.057","article-title":"New viral vaccines","volume":"344","author":"Arvin","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.addr.2021.01.002_bb1015","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/occmed\/kqm110","article-title":"Active and passive immunity, vaccine types, excipients and licensing","volume":"57","author":"Baxter","year":"2007","journal-title":"Occup. Med. (Lond.)"},{"key":"10.1016\/j.addr.2021.01.002_bb1020","first-page":"513","article-title":"Treatment of acute non-chlamydial salpingitis. Study of the efficacy and tolerance of a single-therapy antibiotic: augmentin","volume":"17","author":"Tison","year":"1988","journal-title":"J. Gynecol. Obstet. Biol. Reprod. (Paris)"},{"key":"10.1016\/j.addr.2021.01.002_bb1025","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.3389\/fmicb.2019.02881","article-title":"Recent progress in vaccine development against chikungunya virus","volume":"10","author":"Gao","year":"2019","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.addr.2021.01.002_bb1030","article-title":"Immunogenicity and efficacy evaluation of subunit astrovirus vaccines","volume":"7","author":"Bidokhti","year":"2019","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.addr.2021.01.002_bb1035","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/dth.12330","article-title":"Commentary regarding: efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. H Lal, AL Cunningham, O Godeaux et al., N. Engl. J. Med. 372:2087\u20132096, 2015","volume":"29","author":"Yancey","year":"2016","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.addr.2021.01.002_bb1040","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70\u00a0years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2021.01.002_bb1045","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1016\/j.vaccine.2014.04.016","article-title":"Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice","volume":"32","author":"Coleman","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.002_bb1050","author":"MigVax"},{"key":"10.1016\/j.addr.2021.01.002_bb1055","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13024-020-00375-7","article-title":"Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders","volume":"15","author":"Machhi","year":"2020","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.addr.2021.01.002_bb1060","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41577-020-0402-6","article-title":"T cell responses in patients with COVID-19","volume":"20","author":"Chen","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2021.01.002_bb1065","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13045-017-0469-0","article-title":"Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I\/II multicenter clinical trial","volume":"10","author":"Qian","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.addr.2021.01.002_bb1070","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1200\/JCO.2011.39.8495","article-title":"Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation","volume":"31","author":"Icheva","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2021.01.002_bb1075","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1182\/blood-2010-01-262089","article-title":"Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation","volume":"116","author":"Feuchtinger","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.addr.2021.01.002_bb1080","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.3389\/fimmu.2019.02076","article-title":"Virus (HEV)-specific T cell receptor cross-recognition: implications for immunotherapy","volume":"10","author":"Soon","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2021.01.002_bb1085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008340","article-title":"Combination immunotherapy with anti-PD-L1 antibody and depletion of regulatory T cells during acute viral infections results in improved virus control but lethal immunopathology","volume":"16","author":"David","year":"2020","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.addr.2021.01.002_bb1090","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.immuni.2016.04.022","article-title":"Costimulatory and coinhibitory receptor pathways in infectious disease","volume":"44","author":"Attanasio","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.addr.2021.01.002_bb1095","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.4049\/jimmunol.1101612","article-title":"Virus-specific CD8+ T cells upregulate programmed death-1 expression during acute friend retrovirus infection but are highly cytotoxic and control virus replication","volume":"187","author":"Zelinskyy","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2021.01.002_bb1100","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.jhep.2007.12.014","article-title":"Restoration of HCV-specific T cell functions by PD-1\/PD-L1 blockade in HCV infection: effect of viremia levels and antiviral treatment","volume":"48","author":"Urbani","year":"2008","journal-title":"J. Hepatol."},{"key":"10.1016\/j.addr.2021.01.002_bb1105","article-title":"PD-L1 expression on retrovirus-infected cells mediates immune escape from CD8+ T cell killing","volume":"11","author":"Akhmetzyanova","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.addr.2021.01.002_bb1110","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.addr.2021.01.002_bb1115","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1365-2567.2012.03590.x","article-title":"Dendritic cell-based immunity and vaccination against hepatitis C virus infection","volume":"136","author":"Zhou","year":"2012","journal-title":"Immunology"},{"key":"10.1016\/j.addr.2021.01.002_bb1120","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.2217\/fon.12.125","article-title":"Dendritic cell-based vaccines: barriers and opportunities","volume":"8","author":"Cintolo","year":"2012","journal-title":"Future Oncol."},{"key":"10.1016\/j.addr.2021.01.002_bb1125","article-title":"Cell-based therapy for severe COVID-19 patients: clinical trials and cost-utility","author":"Golchin","year":"2020","journal-title":"Stem Cell Rev. Rep."},{"key":"10.1016\/j.addr.2021.01.002_bb1130","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/PPO.0b013e3181eb33d7","article-title":"Cellular vaccine approaches","volume":"16","author":"Le","year":"2010","journal-title":"Cancer J."},{"key":"10.1016\/j.addr.2021.01.002_bb1135","first-page":"197","article-title":"Sipuleucel-T (provenge) injection: the first immunotherapy agent (vaccine) for hormone-refractory prostate cancer","volume":"36","author":"Anassi","year":"2011","journal-title":"P T"},{"key":"10.1016\/j.addr.2021.01.002_bb1140","author":"Centers for Drug Control anf Prevention"},{"key":"10.1016\/j.addr.2021.01.002_bb1145","author":"University of Manitoba"},{"key":"10.1016\/j.addr.2021.01.002_bb1150","doi-asserted-by":"crossref","first-page":"589833","DOI":"10.3389\/fimmu.2020.589833","article-title":"Adjuvants for coronavirus vaccines","volume":"11","author":"Liang","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2021.01.002_bb1155","doi-asserted-by":"crossref","first-page":"106717","DOI":"10.1016\/j.intimp.2020.106717","article-title":"Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses","volume":"86","author":"Gupta","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.addr.2021.01.002_bb1160","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1166\/jbn.2014.2033","article-title":"A special issue on reviews in nanomedicine, drug delivery and vaccine development","volume":"10","author":"Nalwa","year":"2014","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.addr.2021.01.002_bb1165","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1038\/nm1210","article-title":"Targeting the innate immune response with improved vaccine adjuvants","volume":"11","author":"Pashine","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2021.01.002_bb1170","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1166\/jbn.2014.1984","article-title":"Approaches to tuberculosis mucosal vaccine development using nanoparticles and microparticles: a review","volume":"10","author":"Caetano","year":"2014","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.addr.2021.01.002_bb1175","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.0818-9641.2004.01272.x","article-title":"Vaccine adjuvants: current state and future trends","volume":"82","author":"Petrovsky","year":"2004","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.addr.2021.01.002_bb1180","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/15058","article-title":"D. O'Hagan, Advances in vaccine adjuvants","volume":"17","author":"Singh","year":"1999","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2021.01.002_bb1185","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/14760584.2018.1434000","article-title":"Current challenges for cancer vaccine adjuvant development","volume":"17","author":"Bowen","year":"2018","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.addr.2021.01.002_bb1190","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/sj.clpt.6100394","article-title":"Vaccine immunopotentiators of the future","volume":"82","author":"Schijns","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2021.01.002_bb1195","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nri1391","article-title":"Toll-like receptor signalling","volume":"4","author":"Akira","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2021.01.002_bb1200","doi-asserted-by":"crossref","first-page":"486","DOI":"10.4161\/hv.19229","article-title":"MF59 oil-in-water emulsion in combination with a synthetic TLR4 agonist (E6020) is a potent adjuvant for a combination Meningococcus vaccine","volume":"8","author":"Singh","year":"2012","journal-title":"Hum. Vaccin Immunother."},{"key":"10.1016\/j.addr.2021.01.002_bb1205","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jconrel.2005.10.010","article-title":"D.T. O'Hagan, Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency","volume":"110","author":"Kazzaz","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2021.01.002_bb1210","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.vaccine.2006.06.084","article-title":"Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: implications for a subunit vaccine","volume":"25","author":"Zakhartchouk","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.002_bb1215","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.vaccine.2016.11.064","article-title":"The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection","volume":"35","author":"Jiaming","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.002_bb1220","doi-asserted-by":"crossref","first-page":"8597","DOI":"10.1128\/JVI.00983-14","article-title":"Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB\/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine","volume":"88","author":"Iwata-Yoshikawa","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2021.01.002_bb1225","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.2174\/092986711795933740","article-title":"Aluminium vaccine adjuvants: are they safe?","volume":"18","author":"Tomljenovic","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.addr.2021.01.002_bb1230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2013.12.007","article-title":"Immunomodulatory properties of the vaccine adjuvant alum","volume":"28","author":"Oleszycka","year":"2014","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.addr.2021.01.002_bb1235","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0169-409X(98)00008-8","article-title":"Aluminium compounds as vaccine adjuvants","volume":"32","author":"Gupta","year":"1998","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2021.01.002_bb1240","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.smim.2013.05.007","article-title":"D.T. O'Hagan, Vaccine adjuvant formulations: a pharmaceutical perspective","volume":"25","author":"Brito","year":"2013","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.addr.2021.01.002_bb1245","first-page":"406","article-title":"Mechanism of immunopotentiation and safety of aluminium adjuvants","volume":"3","author":"Hogenesch","year":"2012","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2021.01.002_bb1250","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.vaccine.2005.08.055","article-title":"A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralizing and protective antibody responses","volume":"24","author":"Spruth","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.002_bb1255","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1089\/104454904323145272","article-title":"Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB\/c mice","volume":"23","author":"Tang","year":"2004","journal-title":"DNA Cell Biol."},{"key":"10.1016\/j.addr.2021.01.002_bb1260","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41426-018-0056-7","article-title":"Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus","volume":"7","author":"Deng","year":"2018","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.addr.2021.01.002_bb1265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112602","article-title":"Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen","volume":"9","author":"Lan","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2021.01.002_bb1270","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/ilar.46.3.280","article-title":"Adjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvants","volume":"46","author":"Stills","year":"2005","journal-title":"ILAR J."},{"key":"10.1016\/j.addr.2021.01.002_bb1275","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1016\/j.vaccine.2006.03.074","article-title":"Structure- and oil type-based efficacy of emulsion adjuvants","volume":"24","author":"Jansen","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.002_bb1280","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.vaccine.2011.01.011","article-title":"Adjuvant System AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity","volume":"29","author":"Morel","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.002_bb1285","doi-asserted-by":"crossref","first-page":"6291","DOI":"10.1016\/j.vaccine.2009.02.004","article-title":"MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination","volume":"27","author":"Vesikari","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.002_bb1290","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/0264-410X(95)00089-J","article-title":"Enhancement of humoral response against human influenza vaccine with the simple submicron oil\/water emulsion adjuvant MF59","volume":"13","author":"Ott","year":"1995","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.002_bb1295","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0923-2494(98)80038-2","article-title":"The adjuvant MF59: the 1998 perspective, clinical performance and mechanism of action","volume":"149","author":"Ott","year":"1998","journal-title":"Res. Immunol."},{"key":"10.1016\/j.addr.2021.01.002_bb1300","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.3201\/eid1108.041003","article-title":"SARS vaccine protective in mice","volume":"11","author":"Stadler","year":"2005","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.addr.2021.01.002_bb1305","doi-asserted-by":"crossref","first-page":"13915","DOI":"10.1128\/JVI.79.22.13915-13923.2005","article-title":"Modulation of the immune response to the severe acute respiratory syndrome spike glycoprotein by gene-based and inactivated virus immunization","volume":"79","author":"Kong","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2021.01.002_bb1310","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/cmi.2015.03","article-title":"Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus","volume":"13","author":"Zhang","year":"2016","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.addr.2021.01.002_bb1315","doi-asserted-by":"crossref","first-page":"6871","DOI":"10.1016\/j.vaccine.2012.09.007","article-title":"Nanoemulsion W805EC improves immune responses upon intranasal delivery of an inactivated pandemic H1N1 influenza vaccine","volume":"30","author":"Das","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.002_bb1320","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1016\/j.vaccine.2013.08.064","article-title":"Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5\/Indonesia\/05\/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE\u00a0+\u00a0GLA) adjuvant","volume":"31","author":"Treanor","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.002_bb1325","doi-asserted-by":"crossref","first-page":"4490","DOI":"10.1002\/jps.23311","article-title":"AF03, an alternative squalene emulsion-based vaccine adjuvant prepared by a phase inversion temperature method","volume":"101","author":"Klucker","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2021.01.002_bb1330","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1586\/erv.11.192","article-title":"Development and evaluation of AS03, an Adjuvant System containing alpha-tocopherol and squalene in an oil-in-water emulsion","volume":"11","author":"Garcon","year":"2012","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.addr.2021.01.002_bb1335","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1089\/vim.2010.0028","article-title":"Immunogenicity and protective efficacy in mice and hamsters of a beta-propiolactone inactivated whole virus SARS-CoV vaccine","volume":"23","author":"Roberts","year":"2010","journal-title":"Viral Immunol."},{"key":"10.1016\/j.addr.2021.01.002_bb1340","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1071\/AN18404","article-title":"Efficacy of two adjuvant systems to promote humoral immunity to the pre-proghrelin peptide obestatin in pigs: consequences for the growth of piglets to weaning","volume":"60","author":"Geale","year":"2020","journal-title":"Anim. Prod. Sci."},{"key":"10.1016\/j.addr.2021.01.002_bb1345","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1517\/17425240903018863","article-title":"Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators","volume":"6","author":"Nordly","year":"2009","journal-title":"Expert Opi.n Drug Deliv."},{"key":"10.1016\/j.addr.2021.01.002_bb1350","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1479-0556-3-7","article-title":"A combined nucleocapsid vaccine induces vigorous SARS-CD8+ T-cell immune responses","volume":"3","author":"Azizi","year":"2005","journal-title":"Genet. Vaccines Ther."},{"key":"10.1016\/j.addr.2021.01.002_bb1355","doi-asserted-by":"crossref","first-page":"9939","DOI":"10.1128\/JVI.01048-13","article-title":"Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development","volume":"87","author":"Du","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2021.01.002_bb1360","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1\u20132 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine","volume":"383","author":"Keech","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2021.01.002_bb1365","author":"Vaxine"},{"key":"10.1016\/j.addr.2021.01.002_bb1370","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.addr.2021.01.002_bb1375","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.addr.2015.11.005","article-title":"Designing liposomal adjuvants for the next generation of vaccines","volume":"99","author":"Perrie","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2021.01.002_bb1380","doi-asserted-by":"crossref","first-page":"12522","DOI":"10.1021\/acsnano.0c07197","article-title":"COVID-19 vaccine frontrunners and their nanotechnology design","volume":"14","author":"Chung","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2021.01.002_bb1385","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11100534","article-title":"Recent advances in nanovaccines using biomimetic immunomodulatory materials","volume":"11","author":"Vijayan","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2021.01.002_bb1390","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1208\/s12248-012-9418-6","article-title":"Biodegradable particles as vaccine delivery systems: size matters","volume":"15","author":"Joshi","year":"2013","journal-title":"AAPS J."},{"key":"10.1016\/j.addr.2021.01.002_bb1395","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jconrel.2015.09.046","article-title":"Exploring the role of polymer structure on intracellular nucleic acid delivery via polymeric nanoparticles","volume":"219","author":"Bishop","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2021.01.002_bb1400","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2021.01.002_bb1405","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s11095-010-0241-4","article-title":"Nanoparticle delivery systems in cancer vaccines","volume":"28","author":"Krishnamachari","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2021.01.002_bb1410","doi-asserted-by":"crossref","first-page":"12370","DOI":"10.1021\/acsnano.0c06109","article-title":"Engineering antiviral vaccines","volume":"14","author":"Zhou","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2021.01.002_bb1415","doi-asserted-by":"crossref","first-page":"5932","DOI":"10.7150\/thno.46691","article-title":"Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients","volume":"10","author":"Itani","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.addr.2021.01.002_bb1420","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1016\/j.biomaterials.2011.11.068","article-title":"Thermal-sensitive hydrogel as adjuvant-free vaccine delivery system for H5N1 intranasal immunization","volume":"33","author":"Wu","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2021.01.002_bb1425","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41541-020-0159-8","article-title":"The promise of mRNA vaccines: a biotech and industrial perspective","volume":"5","author":"Jackson","year":"2020","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.addr.2021.01.002_bb1430","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1080\/14760584.2017.1355245","article-title":"Mechanism of action of mRNA-based vaccines","volume":"16","author":"Iavarone","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.addr.2021.01.002_bb1435","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11080360","article-title":"Lipid delivery systems for nucleic-acid-based-drugs: from production to clinical applications","volume":"11","author":"Barba","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2021.01.002_bb1440","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s11095-006-9180-5","article-title":"Lipid-based nanoparticles for nucleic acid delivery","volume":"24","author":"Li","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2021.01.002_bb1445","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nbt.2614","article-title":"Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling","volume":"31","author":"Sahay","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2021.01.002_bb1450","doi-asserted-by":"crossref","first-page":"319","DOI":"10.4155\/tde-2016-0006","article-title":"mRNA vaccine delivery using lipid nanoparticles","volume":"7","author":"Reichmuth","year":"2016","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.addr.2021.01.002_bb1455","author":"Moderna"},{"key":"10.1016\/j.addr.2021.01.002_bb1460","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2 - preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2021.01.002_bb1465","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","article-title":"Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults","volume":"383","author":"Anderson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2021.01.002_bb1470","author":"National Institute of Health"},{"key":"10.1016\/j.addr.2021.01.002_bb1475","author":"Moderna"},{"key":"10.1016\/j.addr.2021.01.002_bb1480","author":"GlobeNewsWire"},{"key":"10.1016\/j.addr.2021.01.002_bb1485","article-title":"Phase 1\/2 study to describe the safety and immunogenicity of a COVID-19 RNA vaccine candidate (BNT162b1) in adults 18 to 55\u00a0years of age: interim report","author":"Mulligan","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.addr.2021.01.002_bb1490","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses","volume":"586","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.addr.2021.01.002_bb1495","author":"Pfizer"},{"key":"10.1016\/j.addr.2021.01.002_bb1500","author":"Pharmaceutical Technology"},{"key":"10.1016\/j.addr.2021.01.002_bb1505","author":"Pharmaceutical Business Review"},{"key":"10.1016\/j.addr.2021.01.002_bb1510","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1038\/s41467-020-17409-9","article-title":"Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice","volume":"11","author":"McKay","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2021.01.002_bb1515","article-title":"Temperature concerns could slow the rollout of new coronavirus vaccines","author":"Jocelyn","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.addr.2021.01.002_bb1520","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1016\/S0006-3495(01)76202-9","article-title":"Spontaneous entrapment of polynucleotides upon electrostatic interaction with ethanol-destabilized cationic liposomes","volume":"80","author":"Maurer","year":"2001","journal-title":"Biophys. J."},{"key":"10.1016\/j.addr.2021.01.002_bb1525","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nbt.1602","article-title":"Rational design of cationic lipids for siRNA delivery","volume":"28","author":"Semple","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2021.01.002_bb1530","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMc2005073","article-title":"SARS-CoV-2 infection in children","volume":"382","author":"Lu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2021.01.002_bb1535","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1126\/science.abb7314","article-title":"Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model","volume":"368","author":"Rockx","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.addr.2021.01.002_bb1540","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.cell.2020.07.024","article-title":"A thermostable mRNA vaccine against COVID-19","volume":"182","author":"Zhang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.addr.2021.01.002_bb1545","first-page":"12","article-title":"An Alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates","author":"Erasmus","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2021.01.002_bb1550","author":"Drug Development and Delivery"},{"key":"10.1016\/j.addr.2021.01.002_bb1555","author":"Novavax"},{"key":"10.1016\/j.addr.2021.01.002_bb1560","author":"Takeda"},{"key":"10.1016\/j.addr.2021.01.002_bb1565","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/d41586-020-01315-7","article-title":"Profile of a killer: the complex biology powering the coronavirus pandemic","volume":"581","author":"Cyranoski","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.addr.2021.01.002_bb1570","doi-asserted-by":"crossref","first-page":"5570","DOI":"10.1021\/acs.nanolett.0c02278","article-title":"Cellular nanosponges inhibit SARS-CoV-2 infectivity","volume":"20","author":"Zhang","year":"2020","journal-title":"Nano Lett."},{"key":"10.1016\/j.addr.2021.01.002_bb1575","series-title":"A Translatable Subunit Nanovaccine for COVID-19","author":"Lixin","year":"2020"},{"key":"10.1016\/j.addr.2021.01.002_bb1580","author":"U.o.W. Institute for Protein Design"},{"key":"10.1016\/j.addr.2021.01.002_bb1585","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41541-020-00223-1","article-title":"Targeting HIV Env immunogens to B cell follicles in nonhuman primates through immune complex or protein nanoparticle formulations","volume":"5","author":"Martin","year":"2020","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.addr.2021.01.002_bb1590","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1586\/erv.10.115","article-title":"Virus-like particles in vaccine development","volume":"9","author":"Roldao","year":"2010","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.addr.2021.01.002_bb1595","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2174\/157016210791208659","article-title":"Virus-like particles as particulate vaccines","volume":"8","author":"Buonaguro","year":"2010","journal-title":"Curr. HIV Res."},{"key":"10.1016\/j.addr.2021.01.002_bb1600","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/nrd2224","article-title":"More than one reason to rethink the use of peptides in vaccine design, Nat","volume":"6","author":"Purcell","year":"2007","journal-title":"Rev. Drug Discov"},{"key":"10.1016\/j.addr.2021.01.002_bb1605","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/protein\/gzq069","article-title":"Virus engineering: functionalization and stabilization","volume":"24","author":"Mateu","year":"2011","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.addr.2021.01.002_bb1610","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.3389\/fimmu.2020.01100","article-title":"Interaction between virus-like particles (VLPs) and pattern recognition receptors (PRRs) from dendritic cells (DCs): toward better engineering of VLPs","volume":"11","author":"Zepeda-Cervantes","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2021.01.002_bb1615","article-title":"Recent progress on the versatility of virus-like particles","volume":"8","author":"Qian","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.addr.2021.01.002_bb1620","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.vaccine.2012.10.083","article-title":"Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development","volume":"31","author":"Kushnir","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.002_bb1625","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.addr.2020.06.024","article-title":"Viral nanoparticles for drug delivery, imaging, immunotherapy, and theranostic applications","volume":"156","author":"Chung","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2021.01.002_bb1630","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.nano.2013.02.009","article-title":"Induction of innate immunity in lungs with virus-like nanoparticles leads to protection against influenza and Streptococcus pneumoniae challenge","volume":"9","author":"Mathieu","year":"2013","journal-title":"Nanomedicine"},{"key":"10.1016\/j.addr.2021.01.002_bb1635","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s12033-012-9598-4","article-title":"Construction and characterization of virus-like particles: a review","volume":"53","author":"Zeltins","year":"2013","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.addr.2021.01.002_bb1640","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ymeth.2006.05.024","article-title":"Virus-like particles: designing an effective AIDS vaccine","volume":"40","author":"Young","year":"2006","journal-title":"Methods"},{"key":"10.1016\/j.addr.2021.01.002_bb1645","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143071","article-title":"A novel virus-like particle based vaccine platform displaying the placental malaria antigen VAR2CSA","volume":"10","author":"Thrane","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2021.01.002_bb1650","doi-asserted-by":"crossref","first-page":"19234","DOI":"10.1038\/srep19234","article-title":"Plug-and-Display: decoration of Virus-Like Particles via isopeptide bonds for modular immunization","volume":"6","author":"Brune","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2021.01.002_bb1655","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/1743-422X-10-129","article-title":"A novel platform for virus-like particle-display of flaviviral envelope domain III: induction of Dengue and West Nile virus neutralizing antibodies","volume":"10","author":"Chua","year":"2013","journal-title":"Virol. J."},{"key":"10.1016\/j.addr.2021.01.002_bb1660","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1586\/14760584.2015.1046440","article-title":"Enveloped virus-like particle platforms: vaccines of the future?","volume":"14","author":"Pitoiset","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.addr.2021.01.002_bb1665","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.addr.2014.10.023","article-title":"Formulation and stabilization of recombinant protein based virus-like particle vaccines","volume":"93","author":"Jain","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2021.01.002_bb1670","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ymeth.2006.07.018","article-title":"Virus-like particles: passport to immune recognition","volume":"40","author":"Grgacic","year":"2006","journal-title":"Methods"},{"key":"10.1016\/j.addr.2021.01.002_bb1675","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/jama.1983.03330300029028","article-title":"Newly licensed hepatitis B vaccine. Known safety and unknown risks","volume":"249","author":"Gerety","year":"1983","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2021.01.002_bb1680","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1492-7535.2005.01155.x","article-title":"Antibody response to Engerix-B and Recombivax-HB hepatitis B vaccination in end-stage renal disease","volume":"9","author":"Lacson","year":"2005","journal-title":"Hemodial. Int."},{"key":"10.1016\/j.addr.2021.01.002_bb1685","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/jnci\/djj144","article-title":"Who invented the VLP cervical cancer vaccines?","volume":"98","author":"McNeil","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.addr.2021.01.002_bb1690","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.vetmic.2010.12.008","article-title":"One dose of a porcine circovirus 2 subunit vaccine induces humoral and cell-mediated immunity and protects against porcine circovirus-associated disease under field conditions","volume":"149","author":"Martelli","year":"2011","journal-title":"Vet. Microbiol."},{"key":"10.1016\/j.addr.2021.01.002_bb1695","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/bit.26890","article-title":"Synthetic biology for bioengineering virus-like particle vaccines","volume":"116","author":"Charlton Hume","year":"2019","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.addr.2021.01.002_bb1700","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00430-014-0374-x","article-title":"Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1\/Pre-S2\/S vaccine","volume":"204","author":"Shouval","year":"2015","journal-title":"Med. Microbiol. Immunol."},{"key":"10.1016\/j.addr.2021.01.002_bb1705","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.tibtech.2013.09.002","article-title":"Virus-like particle-based human vaccines: quality assessment based on structural and functional properties","volume":"31","author":"Zhao","year":"2013","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.addr.2021.01.002_bb1710","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/jnci\/djz074","article-title":"Efficacy, Safety, and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine: an interim analysis of a randomized clinical trial","volume":"112","author":"Qiao","year":"2020","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.addr.2021.01.002_bb1715","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1056\/NEJMc1803554","article-title":"Improved titers against influenza drift variants with a nanoparticle vaccine","volume":"378","author":"Shinde","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2021.01.002_bb1720","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jbiotec.2019.10.007","article-title":"Preparation of virus-like particle mimetic nanovesicles displaying the S protein of Middle East respiratory syndrome coronavirus using insect cells","volume":"306","author":"Kato","year":"2019","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.addr.2021.01.002_bb1725","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.antiviral.2016.12.019","article-title":"Novel chimeric virus-like particles vaccine displaying MERS-CoV receptor-binding domain induce specific humoral and cellular immune response in mice","volume":"140","author":"Wang","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.addr.2021.01.002_bb1730","doi-asserted-by":"crossref","first-page":"6606","DOI":"10.1016\/j.vaccine.2011.06.111","article-title":"Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV","volume":"29","author":"Liu","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.002_bb1735","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.vaccine.2007.11.092","article-title":"Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV","volume":"26","author":"Lokugamage","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.002_bb1740","author":"Dynavax"},{"key":"10.1016\/j.addr.2021.01.002_bb1745","author":"Review"},{"key":"10.1016\/j.addr.2021.01.002_bb1750","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0216533","article-title":"Immunogenicity and safety of a quadrivalent plant-derived virus like particle influenza vaccine candidate-Two randomized Phase II clinical trials in 18 to 49 and >\/=50\u00a0years old adults","volume":"14","author":"Pillet","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2021.01.002_bb1755","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/s41422-020-00392-7","article-title":"A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice","volume":"30","author":"Lu","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.addr.2021.01.002_bb1760","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaw2853","article-title":"Synthetic self-assembling ADDomer platform for highly efficient vaccination by genetically encoded multiepitope display","volume":"5","author":"Vragniau","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.addr.2021.01.002_bb1765","author":"University of Bristol"},{"key":"10.1016\/j.addr.2021.01.002_bb1770","doi-asserted-by":"crossref","DOI":"10.3390\/v12050486","article-title":"Repurposing antiviral protease inhibitors using extracellular vesicles for potential therapy of COVID-19","volume":"12","author":"Kumar","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.addr.2021.01.002_bb1775","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.cmi.2020.03.024","article-title":"Follow-up of asymptomatic patients with SARS-CoV-2 infection","volume":"26","author":"Zhou","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.addr.2021.01.002_bb1780","author":"Codiak"},{"key":"10.1016\/j.addr.2021.01.002_bb1785","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase 1\/2 study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X21000028?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X21000028?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:04:39Z","timestamp":1759208679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X21000028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":356,"alternative-id":["S0169409X21000028"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2021.01.002","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanocarrier vaccines for SARS-CoV-2","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2021.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2021 Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}